Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Wednesday 20 September 2017, 10am to 5pm

Venue: National Institute for Health and Care Excellence
10 Spring Gardens
London
SW1A 2BU

Present: 1. Dr Amanda Adler Present for all notes
2. Dr Sanjeev Patel Present for all notes
3. Dr Ray Armstrong Present for all notes
4. Professor John Cairns Present for all notes
5. Mr Diar Fattah Present for all notes
6. Ms Susan Faulds Present for all notes
7. Dr Mark Glover Present for all notes
8. Mr Richard James Hoddes Present for all notes
9. Dr Sanjay Kinra Present for all notes
10. Dr Miriam McCarthy Present for all notes
11. Dr Stephen Smith Present for all notes
12. Professor Ken Stein Present for all notes
13. Mr Nigel Westwood Present for all notes
14. Dr Stuart Williams Present for all notes

In attendance:
Elisabeth George Associate Director, National Institute for Health and Care Excellence Present for all notes
Jeremy Powell Project Manager, National Institute for Health and Care Excellence Present for all notes
Bashama Anjum Administrator, National Institute for Health and Care Excellence Present for all notes
Ahmed Elsada Technical Advisor, Technology Appraisals, National Institute for Health and Care Excellence Present for notes 18 to 43
Jasdeep Hayre Technical Advisor, Technology Appraisals, National Institute for Health and Care Excellence Present for notes 1 to 17
Thomas Palmer Technical Analyst, National Institute for Health and Care Present for notes 1 to 17
Ross Dent  
Technical Analyst, National Institute for Health and Care Excellence  
Present for notes 18 to 30

Orsolya Balogh  
Technical Analyst, National Institute for Health and Care Excellence  
Present for notes 31 to 43

Mr Malcolm Qualie  
Present for notes 5 to 13

Dr Richard Nicholas  
Consultant Neurologist, Imperial Healthcare NHS Trust – clinical expert, nominated by the MS Trust  
Present for notes 5 to 13

Dr Waqar Rashid  
Consultant Neurologist, Hurstwood Park Neurological Centre – clinical expert, nominated by the Association of British Neurologists  
Present for notes 5 to 13

Ms Christine Chapman  
Patient expert, nominated by the MS Society  
Present for notes 5 to 13

Ms Amy Mackelden  
Patient expert, nominated by the MS Trust  
Present for notes 5 to 13

Rui Duarte  
Liverpool Reviews and Implementation Group  
Present for notes 1 to 15

James Mahon  
Liverpool Reviews and Implementation Group  
Present for notes 1 to 15

Steve Edwards  
Head of HTA - Evidence Review Group – BMJ Group  
Present for notes 18 to 28 and notes 31 to 41

Tracey Jhita  
Health Economics Manager - Evidence Review Group – BMJ Group  
Present for notes 18 to 28

Kayleigh Kew  
HTA Analyst - Evidence Review Group – BMJ Group  
Present for notes 18 to 28

Charlotta Karner  
HTA Analysis Manager - Evidence Review Group – BMJ Group  
Present for notes 31 to 41

Peter Cain  
Health Economist - Evidence Review Group – BMJ Group  
Present for notes 31 to 41

Non-public observers:

Helen Barnett  
Senior Medical Editor, Present for all notes
Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of cladribine tablets for treating relapsing-remitting multiple sclerosis [ID64], tivozanib for treating renal cell carcinoma [ID591] and lenvatinib with everolimus for previously treated advanced renal cell carcinoma [ID1029].

2. The Chair welcomed Dr Stephen Smith to his first meeting as a member of the Appraisal Committee

3. Apologies were received from Mr Mark Chapman, Dr Sumeet Gupta, Dr Nigel de Kare Silver, Mr Christopher O’Regan, Professor Stephen Palmer, Dr Danielle Preedy, Ms Marta Soares, and Professor Nicky Welton.

Any other Business

4. The Committee were given an update on the progress of appraisals that had been discussed at previous meetings and the papers being presented at this month’s NICE Board meeting.

Appraisal of cladribine tablets for treating relapsing-remitting multiple sclerosis [ID64]

Part 1 – Open session

5. The Chair welcomed the invited experts: Mr Malcolm Qualie, Dr Richard Nicholas, Dr Waqar Rashid, Ms Christine Chapman, Ms Amy Mackelden, James Mahon and Rui Duarte to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Merck to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Ray Armstrong, Professor John Cairns, Mr Diar Fattah, Ms Susan Faulds, Dr Mark Glover, Mr Richard James Hoddes, Dr Sanjay Kinra, Dr Miriam McCarthy, Dr Stephen Smith, Professor Ken Stein, Mr Nigel Westwood, Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be
considered as part of the appraisal of cladribine tablets for treating relapsing-remitting multiple sclerosis [ID64].

8. The Chair asked all NICE Staff to declare any relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cladribine tablets for treating relapsing-remitting multiple sclerosis [ID64].

9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

9.1. Mr Malcolm Qualie, Ms Christine Chapman, Ms Amy Mackelden, James Mahon and Rui Duarte declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cladribine tablets for treating relapsing-remitting multiple sclerosis [ID64].

9.2. Dr Richard Nicholas declared a personal specific financial interest as he has received payments from a number of pharmaceutical companies, including Biogen and Roche.

9.2.1. It was agreed that this declaration would not prevent Dr Nicholas from participating in this section of the meeting.

9.3. Dr Waqar Rashid declared a personal specific financial interest as he has received payments from a number of pharmaceutical companies, including Novartis, Roche and Teva.

9.3.1. It was agreed that this declaration would not prevent Dr Rashid from participating in this section of the meeting.

10. The Chair introduced the lead team, Dr Mark Glover, Miriam McCarthy and Nigel Westwood who gave presentations on the clinical effectiveness and cost effectiveness of cladribine tablets for treating relapsing-remitting multiple sclerosis [ID64].

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session
14. Discussion on confidential information continued. This information was supplied by
the company.

15. The Chair then thanked the Evidence Review Group representatives for their
attendance, participation and contribution to the appraisal and they left the
meeting.

16. The Committee continued to discuss the clinical and cost effectiveness of
cladribine tablets for treating relapsing-remitting multiple sclerosis [ID64].

16.1. The committee decision was based on consensus.

17. The Committee instructed the technical team to prepare the Final Appraisal
Determination (FAD) in line with their decisions.

Appraisal of tivozanib for treating renal cell carcinoma [ID591]

Part 1 – Open session

18. The Chair welcomed the invited experts: Professor Peter Clark, Steve Edwards,
Kayleigh Kew, Tracey Jhita to the meeting and they introduced themselves to the
Committee.

19. The Chair welcomed company representatives from Eusapharma to the meeting.

20. The Chair asked all Committee members to declare any relevant interests

20.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Ray Armstrong, Professor John
Cairns, Mr Diar Fattah, Ms Susan Faulds, Dr Mark Glover, Mr Richard
James Hoddes, Dr Sanjay Kinra, Dr Miriam McCarthy, Dr Stephen Smith,
Professor Ken Stein, Mr Nigel Westwood, Dr Stuart Williams all declared
that they knew of no personal specific financial interest, personal non-
specific financial interest, non-personal specific financial interest, non-
personal non-specific financial interest, personal specific family interest
or personal non-specific family interest for any of the technologies to be
considered as part of the appraisal of tivozanib for treating renal cell
carcinoma [ID591].

21. The Chair asked all NICE Staff to declare any relevant interests.

21.1. All declared that they knew of no personal specific financial interest,
personal non-specific financial interest, non-personal specific financial
interest, non-personal non-specific financial interest, personal specific
family interest or personal non-specific family interest for any of the
technologies to be considered as part of the appraisal of tivozanib for
treating renal cell carcinoma [ID591].

22. The Chair asked all other invited guests (assessment group/ERG and invited
experts, not including observers) to declare their relevant interests.

22.1. All declared that they knew of no personal specific financial interest,
personal non-specific financial interest, non-personal specific financial
interest, non-personal non-specific financial interest, personal specific
family interest or personal non-specific family interest for any of the
technologies to be considered as part of the appraisal of tivozanib for treating renal cell carcinoma [ID591].

23. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

24. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

25. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

26. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

27. Discussion on confidential information continued. This information was supplied by the company.

28. The Chair then thanked the Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

29. The Committee continued to discuss the clinical and cost effectiveness of tivozanib for treating renal cell carcinoma [ID591].

29.1. The committee decision was based on consensus.

30. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of lenvatinib with everolimus for previously treated advanced renal cell carcinoma [ID1029]

Part 1 – Open session

31. The Chair welcomed the invited experts: Professor Peter Clark, Steve Edwards, Peter Cain, Charlotta Karner to the meeting and they introduced themselves to the Committee.

32. The Chair welcomed company representatives from Eisai to the meeting.

33. The Chair asked all Committee members to declare any relevant interests

33.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Ray Armstrong, Professor John Cairns, Mr Diar Fattah, Ms Susan Faulds, Dr Mark Glover, Mr Richard James Hoddes, Dr Sanjay Kinra, Dr Miriam McCarthy, Dr Stephen Smith, Professor Ken Stein, Mr Nigel Westwood, Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-
specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenvatinib with everolimus for previously treated advanced renal cell carcinoma [ID1029].

34. The Chair asked all NICE Staff to declare any relevant interests.

34.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenvatinib with everolimus for previously treated advanced renal cell carcinoma [ID1029].

35. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

35.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenvatinib with everolimus for previously treated advanced renal cell carcinoma [ID1029].

36. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

37. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

38. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

39. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

40. Discussion on confidential information continued. This information was supplied by the company.

41. The Chair then thanked the Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

42. The Committee continued to discuss the clinical and cost effectiveness of lenvatinib with everolimus for previously treated advanced renal cell carcinoma [ID1029].
42.1. The committee decision was based on consensus.

43. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting
Wednesday, 16 October 2017 at 10am to 5pm National Institute for Health and Care Excellence, 10 Spring Gardens London, SW1A 2BU